Loading...
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 HCV in interferon ineligible/intolerant individuals
BACKGROUND: Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offer two options for interferon-ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/rib...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4077973/ https://ncbi.nlm.nih.gov/pubmed/24677184 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.27151 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|